Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

PRTA | Prothena Corporation plc

Healthcare | Biotechnology | Ireland | NASD

Index	RUT	P/E	-	EPS (ttm)	-2.78	Insider Own	5.35%	Shs Outstand	52.10M	Perf Week	-5.39%
Market Cap	2.58B	Forward P/E	-	EPS next Y	-4.07	Insider Trans	-9.83%	Shs Float	50.67M	Perf Month	-11.26%
Income	-140.87M	PEG	-	EPS next Q	-0.32	Inst Own	96.62%	Short Float / Ratio	8.44% / 11.18	Perf Quarter	-29.34%
Sales	57.63M	P/S	44.83	EPS this Y	-34.80%	Inst Trans	-4.08%	Short Interest	4.28M	Perf Half Y	1.24%
Book/sh	10.87	P/B	4.44	EPS next Y	-22.35%	ROA	-22.18%	Target Price	93.33	Perf Year	-16.81%
Cash/sh	12.34	P/C	3.91	EPS next 5Y	-0.60%	ROE	-28.49%	52W Range	45.06 - 79.65	Perf YTD	-19.92%
Dividend	-	P/FCF	-	EPS past 5Y	9.51%	ROI	-24.22%	52W High	-39.42%	Beta	0.42
Dividend %	-	Quick Ratio	9.46	Sales past 5Y	4646.93%	Gross Margin	-	52W Low	7.08%	ATR	2.22
Employees	127	Current Ratio	9.46	Sales Q/Q	206.33%	Oper. Margin	-300.61%	RSI (14)	32.37	Volatility	5.56% 3.93%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	-16.63%	Profit Margin	-244.45%	Rel Volume	0.79	Prev Close	48.83
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 03 AMC	Payout	-	Avg Volume	382.33K	Price	48.25
Recom	1.22	SMA20	-7.61%	SMA50	-16.24%	SMA200	-18.16%	Volume	303,884	Change	-1.19%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-24-23	Initiated	SVB Securities	Outperform	$80
Jan-27-23	Initiated	Piper Sandler	Overweight	$94
Nov-04-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$52 → $55
Sep-28-22	Upgrade	BofA Securities	Neutral → Buy
Nov-19-21	Initiated	JMP Securities	Mkt Outperform	$77
Jun-18-21	Upgrade	BofA Securities	Underperform → Neutral	$12 → $49
Jun-08-21	Reiterated	Oppenheimer	Outperform	$45 → $54
May-26-21	Initiated	Citigroup	Buy	$39
Feb-26-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$14 → $28
Feb-12-21	Upgrade	Jefferies	Hold → Buy	$15 → $30
Feb-02-21	Upgrade	BTIG Research	Neutral → Buy	$29
Dec-07-20	Initiated	H.C. Wainwright	Buy	$22
Jul-09-20	Upgrade	Oppenheimer	Perform → Outperform	$16
Nov-19-19	Upgrade	Evercore ISI	In-line → Outperform	$14
May-21-18	Downgrade	Barclays	Equal Weight → Underweight	$14 → $12
Apr-23-18	Downgrade	Jefferies	Buy → Hold
Apr-05-18	Reiterated	Barclays	Overweight	$70 → $50
Nov-20-17	Downgrade	Wedbush	Outperform → Neutral	$75 → $55
Sep-29-17	Reiterated	BTIG Research	Buy	$80 → $77
Sep-15-17	Initiated	RBC Capital Mkts	Outperform	$87

Show Previous Ratings

Sep-28-23 05:01AM	Insider Sell: Prothena Corp PLC's Chief Legal Officer Michael Malecek Sells 5,000 Shares (GuruFocus.com)
Sep-19-23 09:01PM	Insider Sell: Karin Walker Sells 5,000 Shares of Prothena Corp PLC (GuruFocus.com)
Sep-14-23 01:32PM	Insider Sell: Chief Medical Officer Hideki Garren Sells 2,000 Shares of Prothena Corp PLC (GuruFocus.com)
Sep-07-23 12:00PM	Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why (Zacks)
Aug-31-23 04:05PM	Prothena to Participate in Upcoming Healthcare Conferences (Business Wire)
09:13AM	Loading…
Aug-04-23 09:13AM	Prothena (PRTA) Q2 Earnings and Revenues Miss Estimates (Zacks) -7.30%
Aug-03-23 05:55PM	Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:49PM	Prothena: Q2 Earnings Snapshot (AP Finance)
04:05PM	Prothena Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire)
Aug-02-23 07:57AM	Prothena Corporation plc (NASDAQ:PRTA) Shares Could Be 36% Below Their Intrinsic Value Estimate (Simply Wall St.)
Jul-27-23 04:05PM	Prothena to Report Second Quarter 2023 Financial Results on August 3 (Business Wire)
Jul-18-23 05:36PM	The Fight Against Alzheimers Goes Beyond Plaque. Tangles Are a Target, Too. (Barrons.com)
05:36PM	The Fight Against Alzheimer Goes Beyond Plaque. Tangles Are a Target Too. (Barrons.com)
11:30AM	Lilly's (LLY) Donanemab Slows Alzheimer's Disease Progression (Zacks)
Jul-17-23 08:35AM	Prothena Presents New Research in the Treatment of Alzheimers Disease at Alzheimers Association International Conference® 2023 (AAIC®) (Business Wire)
09:22AM	Loading…
Jul-13-23 09:22AM	Biotech Stock Roundup: BIIB, Eisai's Drug Update, NVAX Gains on Deal Amendment (Zacks)
Jul-11-23 04:05PM	Prothena to Present New Data from Alzheimers Disease Programs at Alzheimers Association International Conference® 2023 (AAIC®) (Business Wire)
08:59AM	Prothena (PRTA) Alzheimer's Disease Drug Licensed by BMY (Zacks)
Jul-10-23 04:10PM	Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody (Business Wire)
Jul-07-23 09:51AM	Biogen (BIIB), Eisai Get Full FDA Nod for Leqembi in Alzheimer's (Zacks)
Jun-27-23 04:05PM	Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab (Business Wire)
Jun-12-23 09:25AM	Biogen (BIIB), Eisai Alzheimer Drug Gets FDA Panel Endorsement (Zacks) +5.05%
Jun-08-23 12:41PM	Biogen (BIIB), Eisai's Alzheimer Drug Likely to Get Full FDA Nod (Zacks)
Jun-02-23 04:05PM	Prothena to Participate in Jefferies 2023 Healthcare Conference (Business Wire)
May-16-23 04:05PM	Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors (Business Wire)
May-10-23 06:13AM	Prothena Corporation plc (NASDAQ:PRTA) Analysts Just Trimmed Their Revenue Forecasts By 29% (Simply Wall St.)
May-05-23 12:27PM	Prothena (PRTA) Q1 Earnings and Revenues Miss Estimates (Zacks) +12.02%
May-04-23 06:45PM	Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
05:39PM	Prothena: Q1 Earnings Snapshot (AP Finance)
04:05PM	Prothena Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
04:05PM	Loading…
Apr-27-23 04:05PM	Prothena to Report First Quarter 2023 Financial Results on May 4 (Business Wire)
10:02AM	Analysts Estimate Prothena (PRTA) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-24-23 04:05PM	Prothena to Participate in 2023 Bank of America Healthcare Conference (Business Wire)
Apr-18-23 02:34PM	Companies Like Prothena (NASDAQ:PRTA) Can Afford To Invest In Growth (Simply Wall St.)
Apr-14-23 07:30AM	Walgreens (WBA) Declares Partnership With Prothena Corporation (Zacks)
Apr-13-23 08:00AM	Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimers Disease Clinical Trial (Business Wire) +5.17%
Apr-06-23 01:49PM	Prothena (PRTA) Gains 29% in One Year: Will the Momentum Continue? (Zacks)
Mar-31-23 09:20AM	Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023 (Business Wire)
Mar-21-23 04:05PM	Prothena to Participate in Stifel 2023 Virtual CNS Days (Business Wire)
Mar-14-23 04:05PM	Prothena to Highlight Next Generation Treatments for Alzheimers and Parkinsons Disease at the AD/PD 2023 Meeting (Business Wire)
Mar-01-23 05:20AM	Analysts Just Made A Major Revision To Their Prothena Corporation plc (NASDAQ:PRTA) Revenue Forecasts (Simply Wall St.)
Feb-24-23 11:36AM	Prothena (PRTA) Q4 Earnings and Revenues Beat Estimates (Zacks) +7.11%
Feb-23-23 04:05PM	Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights (Business Wire)
Feb-16-23 04:05PM	Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023 (Business Wire)
Feb-05-23 05:03AM	TipRanks Perfect 10 List: Strong Catalysts Confirm the Bull Thesis on These 2 Stocks (TipRanks)
Feb-03-23 04:05PM	Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-01-23 10:48AM	Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate (Benzinga) -5.09%
Jan-31-23 04:05PM	Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimers Disease (Business Wire)
Jan-15-23 09:01AM	Prothena (NASDAQ:PRTA) shareholder returns have been strong, earning 299% in 3 years (Simply Wall St.)
Dec-14-22 10:38PM	Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares (Business Wire) -8.32%
Dec-13-22 04:12PM	Prothena Announces Proposed Public Offering of Ordinary Shares (Business Wire)
Dec-12-22 11:30AM	Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022 (Business Wire) +5.47%
Nov-29-22 12:42PM	Biogen (BIIB) Down on Report of Death in Alzheimer's Study (Zacks)
Nov-22-22 10:07AM	Prothena (PRTA) Earns Milestone Payment From Novo Nordisk (Zacks)
Nov-21-22 04:05PM	Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy (Business Wire)
Nov-14-22 02:34PM	One Alzheimers drug has failed, but investors are still betting on Biogen and Lilly treatments (MarketWatch) +6.91%
Nov-09-22 06:07AM	Prothena Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) -6.92%
Nov-07-22 09:11AM	Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth (Simply Wall St.)
Nov-04-22 11:13AM	Prothena's (PRTA) Q3 Earnings Miss, Revenues Decline Y/Y (Zacks) -5.43%
Nov-03-22 07:15PM	Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Prothena Reports Third Quarter 2022 Financial Results and Business Highlights (Business Wire)
09:05AM	Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 Meeting (Business Wire)
Oct-27-22 04:05PM	Prothena to Report Third Quarter 2022 Financial Results on November 3rd (GlobeNewswire)
Sep-29-22 09:39AM	LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data (Zacks)
Sep-28-22 12:01PM	Why Biogen, Lilly, and Prothena Stocks Are Skyrocketing Today (Motley Fool) +87.52%
Sep-07-22 11:30AM	Prothena (PRTA) Down 16.9% Since Last Earnings Report: Can It Rebound? (Zacks) +6.40%
Sep-01-22 04:20PM	Prothena to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
04:05PM	Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors (GlobeNewswire)
Aug-09-22 10:37AM	Prothena (PRTA) Q2 Earnings Miss, Pipeline Progress in Focus (Zacks) -8.27%
Aug-08-22 05:45PM	Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Prothena Reports Second Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Aug-07-22 10:27AM	Prothena (NASDAQ:PRTA) delivers shareholders strong 57% CAGR over 3 years, surging 6.6% in the last week alone (Simply Wall St.)
Aug-02-22 04:05PM	Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-01-22 04:05PM	Prothena to Report Second Quarter 2022 Financial Results on August 8th (GlobeNewswire)
Jul-01-22 04:16PM	Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-22-22 10:47AM	Prothena Corporation plc's (NASDAQ:PRTA) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? (Simply Wall St.)
Jun-09-22 11:30AM	Why Is Epizyme (EPZM) Up 51.7% Since Last Earnings Report? (Zacks)
Jun-02-22 04:05PM	Prothena to Participate in Jefferies Healthcare Conference (GlobeNewswire)
May-08-22 08:02AM	These Analysts Just Made A Massive Downgrade To Their Prothena Corporation plc (NASDAQ:PRTA) EPS Forecasts (Simply Wall St.)
May-06-22 12:24PM	Prothena (PRTA) Q1 Earnings Beat, Pipeline Progress in Focus (Zacks)
May-05-22 06:35PM	Prothena (PRTA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -7.17%
04:05PM	Prothena Reports First Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
May-02-22 03:44PM	Why RBC Capital Sees 'Multiple High-Risk' On This Neurology-Focused Stock (Benzinga) +5.04%
Apr-28-22 04:05PM	Prothena to Report First Quarter 2022 Financial Results on May 5th (GlobeNewswire) +10.50%
Apr-26-22 08:30AM	Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimers Disease (GlobeNewswire) -14.05%
Apr-21-22 10:13AM	Prothena (PRTA) Stock Gains 51% in a Year: What Lies Ahead? (Zacks)
Mar-29-22 11:44AM	Prothena (PRTA) IND Application Gets FDA Clearance for AD (Zacks)
Mar-28-22 08:30AM	Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimers Disease (GlobeNewswire)
Mar-21-22 04:05PM	Prothena to Participate in Stifel 2022 Virtual CNS Days (GlobeNewswire)
Mar-16-22 09:20AM	Prothena Highlinghts New Preclinical Data For Alzheimer's, Parkinson's Vaccine Programs (Benzinga) +7.14%
05:30AM	Prothena Presents New Data for Alzheimers and Parkinsons Disease Programs at AD/PD 2022 (GlobeNewswire)
Feb-18-22 10:05AM	Prothena (PRTA) Q4 Earnings Beat, Pipeline Progress in Focus (Zacks)
Feb-17-22 05:45PM	Prothena (PRTA) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.90%
04:05PM	Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights (GlobeNewswire)
Feb-10-22 04:05PM	Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 17, 2022 (GlobeNewswire)
Feb-03-22 05:38PM	Xcel Wealth Management, LLC Buys Affirm Holdings Inc, Bloomin Brands Inc, Skyworks Solutions ... (GuruFocus.com)
03:01PM	Will Prothena (PRTA) Report Negative Q4 Earnings? What You Should Know (Zacks)
02:36PM	10 Biotech Stocks to Buy According to Matthew Strobecks Birchview Capital (Insider Monkey)
Jan-28-22 01:38PM	Bellwether Advisors, LLC Buys Financial Select Sector SPDR, Consumer Discretionary Select ... (GuruFocus.com)
Jan-27-22 01:38PM	Hunter Perkins Capital Management, LLC Buys Canadian Pacific Railway, U.S. ... (GuruFocus.com) -6.76%

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm's clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Malecek Michael J	Chief Legal Officer	Sep 27	Option Exercise	10.27	5,000	51,350	5,000	Sep 27 08:35 PM
Malecek Michael J	Chief Legal Officer	Sep 27	Sale	47.38	5,000	236,885	0	Sep 27 08:35 PM
Walker Karin L	Chief Accounting Officer	Sep 19	Option Exercise	15.04	5,000	75,200	5,000	Sep 19 05:37 PM
Walker Karin L	Chief Accounting Officer	Sep 19	Sale	52.36	5,000	261,807	0	Sep 19 05:37 PM
Garren Hideki	Chief Medical Officer	Sep 13	Option Exercise	24.90	2,000	49,800	2,000	Sep 13 07:33 PM
Smith Brandon S.	Chief Operating Officer	Sep 13	Option Exercise	11.12	4,000	44,480	4,000	Sep 13 07:32 PM
Smith Brandon S.	Chief Operating Officer	Sep 13	Sale	55.49	4,000	221,963	0	Sep 13 07:32 PM
Garren Hideki	Chief Medical Officer	Sep 13	Sale	55.48	2,000	110,952	0	Sep 13 07:33 PM
Karp Carol D.	Chief Regulatory Officer	Sep 06	Option Exercise	12.15	5,000	60,750	5,000	Sep 06 07:42 PM
Karp Carol D.	Chief Regulatory Officer	Sep 06	Sale	54.76	5,000	273,804	0	Sep 06 07:42 PM
Malecek Michael J	Chief Legal Officer	Aug 30	Option Exercise	10.27	5,000	51,350	5,000	Aug 30 07:24 PM
Malecek Michael J	Chief Legal Officer	Aug 30	Sale	55.01	5,000	275,066	0	Aug 30 07:24 PM
Walker Karin L	Chief Accounting Officer	Aug 18	Option Exercise	15.04	5,000	75,200	5,000	Aug 18 08:37 PM
Walker Karin L	Chief Accounting Officer	Aug 18	Sale	57.18	5,000	285,922	0	Aug 18 08:37 PM
Garren Hideki	Chief Medical Officer	Aug 16	Option Exercise	24.90	2,000	49,800	2,000	Aug 16 09:15 PM
Smith Brandon S.	Chief Operating Officer	Aug 16	Option Exercise	11.12	4,000	44,480	4,000	Aug 16 09:15 PM
Smith Brandon S.	Chief Operating Officer	Aug 16	Sale	58.71	4,000	234,844	0	Aug 16 09:15 PM
Garren Hideki	Chief Medical Officer	Aug 16	Sale	58.74	2,000	117,480	0	Aug 16 09:15 PM
Karp Carol D.	Chief Regulatory Officer	Aug 02	Option Exercise	12.15	5,000	60,750	5,000	Aug 02 09:00 PM
Zago Wagner M.	Chief Scientific Officer	Aug 02	Option Exercise	12.15	4,000	48,600	4,000	Aug 02 09:00 PM
Karp Carol D.	Chief Regulatory Officer	Aug 02	Sale	67.01	5,000	335,072	0	Aug 02 09:00 PM
Zago Wagner M.	Chief Scientific Officer	Aug 02	Sale	67.05	4,000	268,182	0	Aug 02 09:00 PM
Malecek Michael J	Chief Legal Officer	Jul 26	Option Exercise	10.27	5,000	51,350	5,000	Jul 26 07:45 PM
Malecek Michael J	Chief Legal Officer	Jul 26	Sale	62.33	5,000	311,638	0	Jul 26 07:45 PM
Walker Karin L	Chief Accounting Officer	Jul 19	Option Exercise	15.04	5,000	75,200	5,000	Jul 19 08:50 PM
Walker Karin L	Chief Accounting Officer	Jul 19	Sale	69.19	5,000	345,943	0	Jul 19 08:50 PM
Garren Hideki	Chief Medical Officer	Jul 12	Option Exercise	24.90	2,000	49,800	2,000	Jul 12 08:45 PM
Smith Brandon S.	Chief Operating Officer	Jul 12	Option Exercise	11.12	4,000	44,480	4,000	Jul 12 08:45 PM
Smith Brandon S.	Chief Operating Officer	Jul 12	Sale	67.51	4,000	270,026	0	Jul 12 08:45 PM
Garren Hideki	Chief Medical Officer	Jul 12	Sale	67.51	2,000	135,027	0	Jul 12 08:45 PM
Karp Carol D.	Chief Regulatory Officer	Jul 05	Option Exercise	12.15	5,000	60,750	5,000	Jul 05 09:33 PM
Zago Wagner M.	Chief Scientific Officer	Jul 05	Option Exercise	12.15	4,000	48,600	4,000	Jul 05 09:32 PM
Karp Carol D.	Chief Regulatory Officer	Jul 05	Sale	68.13	5,000	340,636	0	Jul 05 09:33 PM
Zago Wagner M.	Chief Scientific Officer	Jul 05	Sale	68.16	4,000	272,648	0	Jul 05 09:32 PM
Selkoe Dennis J.	Director	Jul 03	Option Exercise	11.33	5,000	56,650	7,845	Jul 03 06:16 PM
Selkoe Dennis J.	Director	Jul 03	Sale	67.43	5,000	337,150	2,845	Jul 03 06:16 PM
Malecek Michael J	Chief Legal Officer	Jun 28	Option Exercise	10.27	5,000	51,350	5,000	Jun 28 08:45 PM
Malecek Michael J	Chief Legal Officer	Jun 28	Sale	69.82	5,000	349,118	0	Jun 28 08:45 PM
Garren Hideki	Chief Medical Officer	Jun 16	Option Exercise	24.90	7,331	182,542	7,331	Jun 16 07:31 PM
Garren Hideki	Chief Medical Officer	Jun 16	Sale	74.00	7,331	542,494	0	Jun 16 07:31 PM
Garren Hideki	Chief Medical Officer	Jun 14	Option Exercise	24.90	4,669	116,258	4,669	Jun 14 09:15 PM
Smith Brandon S.	Chief Operating Officer	Jun 14	Option Exercise	11.12	5,333	59,303	5,333	Jun 14 09:15 PM
Smith Brandon S.	Chief Operating Officer	Jun 14	Sale	73.98	5,333	394,562	0	Jun 14 09:15 PM
Garren Hideki	Chief Medical Officer	Jun 14	Sale	74.22	4,669	346,516	0	Jun 14 09:15 PM
Zago Wagner M.	Chief Scientific Officer	Jun 07	Option Exercise	26.09	19,000	495,750	19,000	Jun 07 09:49 PM
Karp Carol D.	Chief Regulatory Officer	Jun 07	Option Exercise	13.19	20,000	263,700	20,000	Jun 07 09:49 PM
Karp Carol D.	Chief Regulatory Officer	Jun 07	Sale	71.05	20,000	1,421,009	0	Jun 07 09:49 PM
Zago Wagner M.	Chief Scientific Officer	Jun 07	Sale	71.06	19,000	1,350,224	0	Jun 07 09:49 PM
Malecek Michael J	Chief Legal Officer	May 31	Option Exercise	10.27	5,000	51,350	5,000	May 31 09:30 PM
Malecek Michael J	Chief Legal Officer	May 31	Sale	64.64	5,000	323,223	0	May 31 09:30 PM
Walker Karin L	Chief Accounting Officer	May 19	Option Exercise	15.04	5,000	75,200	5,000	May 19 09:31 PM
Walker Karin L	Chief Accounting Officer	May 19	Sale	74.00	5,000	369,978	0	May 19 09:31 PM
Nguyen Tran	Chief Strategy Officer and CFO	May 17	Option Exercise	26.15	95,000	2,483,950	98,200	May 17 09:53 PM
Kinney Gene G.	President and CEO	May 17	Option Exercise	29.81	45,000	1,341,450	57,793	May 17 09:54 PM
Nguyen Tran	Chief Strategy Officer and CFO	May 17	Sale	73.99	95,000	7,028,921	3,200	May 17 09:53 PM
Kinney Gene G.	President and CEO	May 17	Sale	73.70	45,000	3,316,292	12,793	May 17 09:54 PM
Selkoe Dennis J.	Director	May 03	Option Exercise	18.07	15,000	271,110	17,845	May 05 09:30 PM
Selkoe Dennis J.	Director	May 03	Sale	57.00	15,000	855,000	2,845	May 05 09:30 PM
Malecek Michael J	Chief Legal Officer	Apr 26	Option Exercise	10.27	5,000	51,350	5,000	Apr 28 09:30 PM
Malecek Michael J	Chief Legal Officer	Apr 26	Sale	53.46	5,000	267,292	0	Apr 28 09:30 PM
Walker Karin L	Chief Accounting Officer	Apr 19	Option Exercise	15.04	5,000	75,200	5,000	Apr 21 09:30 PM
Walker Karin L	Chief Accounting Officer	Apr 19	Sale	52.90	5,000	264,480	0	Apr 21 09:30 PM
Malecek Michael J	Chief Legal Officer	Mar 29	Option Exercise	10.27	5,000	51,350	5,000	Mar 31 09:31 PM
Malecek Michael J	Chief Legal Officer	Mar 29	Sale	49.02	5,000	245,123	0	Mar 31 09:31 PM
Walker Karin L	Chief Accounting Officer	Mar 20	Option Exercise	15.04	5,000	75,200	5,000	Mar 22 09:30 PM
Walker Karin L	Chief Accounting Officer	Mar 20	Sale	47.72	5,000	238,610	0	Mar 22 09:30 PM
Walker Karin L	Chief Accounting Officer	Mar 15	Option Exercise	15.04	20,000	300,800	20,000	Mar 17 09:32 PM
Garren Hideki	Chief Medical Officer	Mar 15	Option Exercise	24.90	12,000	298,800	12,000	Mar 17 09:30 PM
Malecek Michael J	Chief Legal Officer	Mar 15	Option Exercise	10.27	15,000	154,050	15,000	Mar 17 09:31 PM
Nguyen Tran	Chief Strategy Officer and CFO	Mar 15	Option Exercise	6.73	10,000	67,300	13,200	Mar 17 09:31 PM
Walker Karin L	Chief Accounting Officer	Mar 15	Sale	48.42	20,000	968,346	0	Mar 17 09:32 PM
Malecek Michael J	Chief Legal Officer	Mar 15	Sale	48.44	15,000	726,592	0	Mar 17 09:31 PM
Garren Hideki	Chief Medical Officer	Mar 15	Sale	48.41	12,000	580,936	0	Mar 17 09:30 PM
Nguyen Tran	Chief Strategy Officer and CFO	Mar 15	Sale	48.43	10,000	484,314	3,200	Mar 17 09:31 PM
Nguyen Tran	Chief Strategy Officer and CFO	Feb 15	Option Exercise	6.73	10,000	67,300	13,200	Feb 17 09:30 PM
Nguyen Tran	Chief Strategy Officer and CFO	Feb 15	Sale	53.34	10,000	533,397	3,200	Feb 17 09:30 PM
Nguyen Tran	Chief Strategy Officer and CFO	Jan 18	Option Exercise	6.73	10,000	67,300	13,200	Jan 20 09:30 PM
Nguyen Tran	Chief Strategy Officer and CFO	Jan 18	Sale	55.53	10,000	555,306	3,200	Jan 20 09:30 PM
Cooke Shane	Director	Jan 10	Option Exercise	6.41	5,000	32,050	5,000	Jan 12 09:31 PM
Cooke Shane	Director	Jan 10	Sale	52.92	5,000	264,608	0	Jan 12 09:31 PM
COLLIER RICHARD T	Director	Jan 05	Option Exercise	6.41	5,000	32,050	6,219	Jan 05 09:38 PM
COLLIER RICHARD T	Director	Jan 05	Sale	52.67	5,000	263,350	1,219	Jan 05 09:38 PM
Ekman Lars	Chair of the Board	Jan 03	Option Exercise	6.41	15,834	101,496	16,077	Jan 05 09:42 PM
Ekman Lars	Chair of the Board	Jan 03	Sale	55.98	15,834	886,407	243	Jan 05 09:42 PM
Nguyen Tran	Chief Strategy Officer and CFO	Dec 21	Option Exercise	6.73	10,000	67,300	13,200	Dec 23 09:30 PM
Nguyen Tran	Chief Strategy Officer and CFO	Dec 21	Sale	58.97	10,000	589,690	3,200	Dec 23 09:30 PM
Cooke Shane	Director	Dec 12	Option Exercise	6.41	5,000	32,050	5,000	Dec 12 09:31 PM
Cooke Shane	Director	Dec 12	Sale	61.04	5,000	305,191	0	Dec 12 09:31 PM
COLLIER RICHARD T	Director	Dec 05	Option Exercise	6.41	5,000	32,050	6,219	Dec 05 09:47 PM
COLLIER RICHARD T	Director	Dec 05	Sale	62.07	5,000	310,356	1,219	Dec 05 09:47 PM
Ekman Lars	Chair of the Board	Dec 01	Option Exercise	6.41	15,834	101,496	16,077	Dec 02 09:30 PM
Garren Hideki	Chief Medical Officer	Dec 01	Option Exercise	24.90	4,000	99,600	4,000	Dec 02 09:30 PM
Ekman Lars	Chair of the Board	Dec 01	Sale	61.60	15,834	975,406	243	Dec 02 09:30 PM
Garren Hideki	Chief Medical Officer	Dec 01	Sale	62.51	4,000	250,040	0	Dec 02 09:30 PM
Malecek Michael J	Chief Legal Officer	Nov 30	Option Exercise	10.27	5,000	51,350	5,000	Dec 02 09:30 PM
Malecek Michael J	Chief Legal Officer	Nov 30	Sale	62.28	5,000	311,376	0	Dec 02 09:30 PM
Nguyen Tran	Chief Strategy Officer and CFO	Nov 23	Option Exercise	6.73	10,000	67,300	13,200	Nov 25 09:31 PM
Nguyen Tran	Chief Strategy Officer and CFO	Nov 23	Sale	61.09	10,000	610,854	3,200	Nov 25 09:31 PM
Walker Karin L	Chief Accounting Officer	Nov 18	Option Exercise	15.04	10,000	150,400	10,000	Nov 18 09:32 PM
Walker Karin L	Chief Accounting Officer	Nov 18	Sale	57.07	10,000	570,709	0	Nov 18 09:32 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PRTA | Prothena Corporation plc

Upgrade your FINVIZ experience